XORTX Therapeutics Inc. Common Stock (XRTX)
XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing targeted therapies for kidney diseases, particularly those involving fluid and electrolyte imbalance. The company specializes in innovative treatments for conditions such as autosomal dominant polycystic kidney disease (ADPKD) and other related disorders, leveraging oral therapeutics to improve patient outcomes.
Company News
XORTX Therapeutics has entered into a securities purchase agreement to sell 1,746,631 common shares at $0.63 per share, expecting to raise approximately $1.1 million for working capital and general corporate purposes.
Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates. SAIC reported a 12% revenue decline Y/Y in the fourth quarter of fiscal 2024 to $1.74 billion, beating the consensus of $1.64 billion. Adjusted EPS of $1.43 was in l...